2025-26 flu low VE; Moderna mRNA-1010 Ph3 data
Key Questions
What is the vaccine effectiveness for the 2025-26 flu season?
VE for adults against H3N2 is estimated at 22-34%. Moderna’s mRNA-1010 showed 26.6% superior effectiveness in adults 50 and older in Phase 3 data.
What flu vaccine recommendations exist for people with COPD?
GOLD guidelines recommend flu vaccination for COPD patients. Both adjuvanted and high-dose vaccines are considered equally effective in adults 65 and older.
When will VRBPAC review the MFLUSIVA flu candidate?
The VRBPAC meeting is scheduled for June 18 to discuss safety and effectiveness. The committee will make recommendations on the candidate.
How do prior flu shots affect uptake in older adults?
Prior flu shots and having a vaccinated spouse are linked to increased uptake. A recent study highlighted these factors in older adult populations.
Are adjuvanted and high-dose flu vaccines equally protective?
A large Kaiser Permanente study found they perform similarly in adults aged 65 and older. Both enhanced options offer comparable protection against flu.
VE 22-34% adults H3N2; Moderna 26.6% superior 50+; COPD/GOLD flu recs. Adjuvanted and high-dose equally effective in 65+. VRBPAC June 18 reviews MFLUSIVA flu candidate.